Articles

On June 10, 2020, the FDA accelerated the approval of a new indication for nivolumab (Opdivo; Bristol Myers Squibb), a PD-1 inhibitor, for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma after fluoropyrimidine-based and platinum-based chemotherapy. Nivolumab has been previously approved for many indications, but this is its first indication for esophageal cancer. Read More ›

From The Editor

By Beth Faiman, PhD, APRN-BC, AOCN

From the Editor

TON - June 2020, Vol 13, No 3

AVBCC 2019 Highlights

TON - June 2020, Vol 13, No 3

Cancer Center Profile

TON - June 2020, Vol 13, No 3

Mayo Clinic is one of the largest providers of bone marrow transplants in the United States, having performed nearly 10,000 stem-cell transplants at its campuses in Arizona, Florida, and Minnesota. At Mayo Clinic in Rochester, MN, approximately 500 transplants are performed each year. Read More ›

First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma

By Phoebe Starr

Renal Cell Carcinoma

TON - June 2020, Vol 13, No 3

Surgery Is a Viable Treatment Option for Patients with Early-Stage Germ Cell Tumors

By Wayne Kuznar

Survivorship

TON - June 2020, Vol 13, No 3

By Phoebe Starr

AACR Highlights

TON - June 2020, Vol 13, No 3

FDA News

FDA Updates

TON - June 2020, Vol 13, No 3

This section provides a brief overview of new cancer drugs or new indications approved by the FDA between April 17, 2020, and May 8, 2020. Read More ›